RxSight, Inc.

NasdaqGM:RXST 주식 보고서

시가총액: US$1.9b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RxSight 관리

관리 기준 확인 3/4

RxSight's CEO는 Ron Kurtz, Jan2016 에 임명되었습니다 의 임기는 8.58 년입니다. 총 연간 보상은 $ 3.08M, 20.6% 로 구성됩니다. 20.6% 급여 및 79.4% 보너스(회사 주식 및 옵션 포함). 는 $ 42.02M 가치에 해당하는 회사 주식의 2.09% 직접 소유합니다. 42.02M. 경영진과 이사회의 평균 재임 기간은 각각 3.9 년과 3 년입니다.

주요 정보

Ron Kurtz

최고 경영자

US$3.1m

총 보상

CEO 급여 비율20.6%
CEO 임기8.8yrs
CEO 소유권2.1%
경영진 평균 재임 기간4yrs
이사회 평균 재임 기간3.2yrs

최근 관리 업데이트

Recent updates

We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Sep 04
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Investing In The Future Of Cataract Surgery: The RxSight Advantage

Aug 13

With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

Aug 03
With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

Jul 12
Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

RxSight: Great Business Model, Stretched Valuations

Jul 10

A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

Jun 20
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

May 09
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

May 05
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation

May 01

Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Apr 16
Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

Mar 24
Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

RxSight Stock: Time To Refocus Following Eye Watering Rally

Jan 16

RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Jan 09
RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Dec 21
We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

Nov 24
Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 11
RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets

RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M

Aug 08

RxSight says FDA requires additional info for approval of light delivery device

Jul 12

RxSight: First And Only Customizable Intraocular Lens

Aug 26

CEO 보상 분석

Ron Kurtz 의 보수는 RxSight 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$3mUS$633k

-US$49m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$62m

Dec 31 2022US$1mUS$563k

-US$67m

Sep 30 2022n/an/a

-US$67m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$5mUS$445k

-US$49m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

US$4m

Mar 31 2021n/an/a

US$17m

Dec 31 2020US$741kUS$310k

US$3m

보상 대 시장: Ron 의 총 보상 ($USD 3.08M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.66M ).

보상과 수익: 회사가 수익성이 없는 동안 Ron 의 보상이 증가했습니다.

CEO

Ron Kurtz (61 yo)

8.8yrs

테뉴어

US$3,081,597

보상

Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...

리더십 팀

이름위치테뉴어보상소유권
Ronald Kurtz
President8.8yrsUS$3.08m2.09%
$ 39.0m
Eric Weinberg
Co-President & Chief Commercial Officer9.3yrsUS$1.65m0.77%
$ 14.5m
Shelley Thunen
Co-President & Chief Financial Officer7.7yrsUS$1.89m0.077%
$ 1.4m
Ilya Goldshleger
Co-President & Chief Operating Officer5.3yrsUS$1.89m0.11%
$ 2.1m
Rebecca Williston
Vice President of Accounting & Financeno data데이터 없음데이터 없음
Matt Haller
Chief Technology Officerno data데이터 없음데이터 없음
Oliver Moravcevic
Vice President of Investor Relationsless than a year데이터 없음데이터 없음
Steve Everly
Senior VP of Sales of North Americaless than a year데이터 없음데이터 없음
Roy Freeman
Senior VP of Marketing & Professional Relations2.8yrs데이터 없음데이터 없음
Caroline Vaughn
Vice President of Human Resources9.2yrs데이터 없음데이터 없음
Scott Gaines
Executive VP of Manufacturing & Commercial Operations2.8yrs데이터 없음데이터 없음
Maureen O'Connell
Executive VP of Clinical & Regulatory Affairs2.6yrs데이터 없음데이터 없음

4.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: RXST 의 관리팀은 경험 ( 3.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Ronald Kurtz
President8.7yrsUS$3.08m2.09%
$ 39.0m
William Link
Director7.9yrsUS$204.98k0.12%
$ 2.2m
Robert Palmisano
Independent Director3.2yrsUS$209.98k0.063%
$ 1.2m
Juliet Tammenoms Bakker
Independent Director9.3yrsUS$209.98k0.092%
$ 1.7m
Jesse Corley
Independent Chairman of the Board9.8yrsUS$257.48k1.29%
$ 24.2m
Tamara Fountain
Independent Director2.8yrsUS$204.98k0.058%
$ 1.1m
Julie Andrews
Independent Director3.2yrsUS$214.98k0.063%
$ 1.2m
Robert Warner
Independent Director3.2yrsUS$212.48k0.063%
$ 1.2m
Shweta Maniar
Independent Director2.8yrsUS$199.98k0.014%
$ 270.2k

3.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: RXST 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.